A practical reference on incretin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-07 and is reviewed periodically as new material appears.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
==== Borderline personality disorder ==== Similar epigenetic alterations in OPRK1 methylation patterns have been linked to borderline personality disorder (BPD), where an imbalance between opioid receptor systems could cause symptoms such as chronic dysphoria, suicidality, and emotional instability. In individuals with BPD, decreased DNA methylation (hypomethylation) in a differentially methylated region (DMR) located within the promoter region, specifically at a cluster of five adjacent CpG sites (CG34–CG38) positioned immediately upstream of core CpG islands (CGI-1 and CGI-2), results in enhanced gene transcription and elevated KOR expression. The DMR hypomethylation in BPD is strategically positioned on the "falling slope" of the gene's methylation gap; a transition zone between the sparsely methylated CpG island promoter and densely methylated downstream regions. This location amplifies the functional consequences of hypomethylation by progressively steepening the methylation gradient, further facilitating transcription initiation at multiple transcription start sites (TSS) distributed throughout the CGI promoter region. Consequently, the decreased methylation rates in the DMR are associated with increased OPRK1 mRNA transcription and heightened KOR protein expression in peripheral white blood cells and, by extension, in central brain regions involved in emotion regulation. Symptom severity in BPD correlates with DMR hypomethylation levels.
The small-pox so fatal and so general amongst us is here entirely harmless by the invention of ingrafting (which is the term they give it). There is a set of old women who make it their business to perform the operation. Every autumn in the month of September, when the great heat is abated, people send to one another to know if any of their family has a mind to have the small-pox. They make parties for this purpose, and when they are met (commonly fifteen or sixteen together) the old woman comes with a nutshell full of the matter of the best sort of small-pox and asks what veins you please to have opened. She immediately rips open that you offer to her with a large needle (which gives you no more pain than a common scratch) and puts into the vein as much venom as can lye upon the head of her needle, and after binds up the little wound with a hollow bit of shell, and in this manner opens four or five veins. ... The children or young patients play together all the rest of the day and are in perfect health till the eighth. Then the fever begins to seize them and they keep their beds two days, very seldom three. They have very rarely above twenty or thirty in their faces, which never mark, and in eight days time they are as well as before the illness. ... There is no example of any one that has died in it, and you may believe I am very well satisfied of the safety of the experiment since I intend to try it on my dear little son.
Freeze-casting, also frequently referred to as ice-templating, is a technique that exploits the highly anisotropic solidification behavior of a solvent (often, but not exclusively, water) in a well-dispersed solution or slurry to controllably template directionally porous ceramics, polymers, metals and their hybrids. By subjecting a slurry to a directional temperature gradient, ice crystals will nucleate on one side and grow along the temperature gradient. The ice crystals will redistribute the dissolved substance and the suspended particles as they grow within the slurry, effectively templating the ingredients that are distributed in the slurry. Once solidification has ended, the frozen, templated composite is placed into a freeze-dryer to remove the ice. The resulting green body contains anisotropic macropores in a replica of the sublimated ice crystals and structures from micropores to nacre-like packing between the ceramic or metal particles in the walls. The walls templated by the morphology of the ice crystals often show unilateral features. These together build a hierarchically structured cellular structure. This structure is often sintered for metals and ceramics, and crosslinked for polymers, to consolidate the particulate walls and provide strength to the porous material. The porosity left by the sublimation of solidified fluid is typically between 2–200 μm.
== Synthetic history == Vanillin was first isolated as a relatively pure substance in 1858 by Théodore Nicolas Gobley, who obtained it by evaporating a vanilla extract to dryness and recrystallizing the resulting solids from hot water. In 1874, the German scientists Ferdinand Tiemann and Wilhelm Haarmann deduced its chemical structure, at the same time finding a synthesis for vanillin from coniferin, a glucoside of coniferyl alcohol found in pine bark. Tiemann and Haarmann founded a company Haarmann and Reimer (now part of Symrise) and started the first industrial production of vanillin using their process (now known as the Reimer–Tiemann reaction) in Holzminden, Germany. In 1876, Karl Reimer synthesized vanillin (2) from guaiacol (1).
Neither the extent of coronary disease nor the appearance of the collateral vessels during angiography differed between the two groups, leading Kolibash to conclude that angiography is inadequate in and of itself to evaluate the functional significance of collateral vessels, and that "several physiologic variables" are most likely responsible for myocardial status in any given clinical situation. That so many adequately collateralized areas showed no evidence of subsequent improvement in myocardial perfusion also provided evidence that collaterals may often be of little or no significance. However, it is possible that such collaterals appeared too late after infarction to significantly improve overall perfusion. Since Kolibash's study, newer techniques have been used effectively to investigate the issues he raised and to characterize both the mechanism of the transformation of the native collaterals and assess their impact on myocardial perfusion and function—among them percutaneous transluminal coronary angioplasty (PTCA), ergovine-provocative spasm tests, and myocardial perfusion studies. Using PTCA, Rentrop demonstrated that collateral vessel filling jumps dramatically during coronary occlusion by balloon inflation—within ninety seconds of total occlusion. Filling improved in 15 of 16 patients; neither chest pain nor pre-inflation angina correlated with the extent of collateral filling, and coronary spasm did not occur.
Sources: en.wikipedia.org
In eukaryotes, ribosomes are present in mitochondria (sometimes called mitoribosomes) and in plastids such as chloroplasts (also called plastoribosomes). They also consist of large and small subunits bound together with proteins into one 70S particle. These ribosomes are similar to those of bacteria and these organelles are thought to have originated as symbiotic bacteria. Of the two, chloroplastic ribosomes are closer to bacterial ones than mitochondrial ones are. Many pieces of ribosomal RNA in the mitochondria are shortened, and in the case of 5S rRNA, replaced by other structures in animals and fungi. In particular, Leishmania tarentolae has a minimalized set of mitochondrial rRNA. In contrast, plant mitoribosomes have both extended rRNA and additional proteins as compared to bacteria, in particular, many pentatricopetide repeat proteins. The cryptomonad and chlorarachniophyte algae may contain a nucleomorph that resembles a vestigial eukaryotic nucleus. Eukaryotic 80S ribosomes may be present in the compartment containing the nucleomorph.
=== 2.1a === VESA announced version 2.1a of the DisplayPort standard on 8 January 2024. This version replaces the DP40 cable certification with the new DP54 certification, which tests DisplayPort cables for proper operation at the UHBR13.5 (54 Gbit/s) speed introduced in version 2.0.
== Adverse effects == Protamine has been reported to cause allergic reactions in patients who are allergic to fish, diabetics using insulin preparations containing protamine, and vasectomized or infertile men. These occur at rates ranging from 0.28% to 6%. Avoiding rapid infusion of protamine sulfate and pre-treating at-risk patients with histamine receptor antagonists (H1 and H2) and steroids may minimize these reactions. A 5 to 10 mg test dose is recommended following pretreatment before administering the full dose.
From this revolution, the 1950s also saw the advent of paper chromatography, reversed-phase partition chromatography (RPC), and hydrophobic interaction chromatography (HIC). The first gels for use in LC were created using cross-linked dextrans (Sephadex) in an attempt to realize Synge's prediction that a unique single-piece stationary phase could provide an ideal chromatographic solution. In the 1960s, polyacrylamide and agarose gels were created in a further attempt to create a single-piece stationary phase, but the purity of and stability of available components did not prove useful for implementation in the HPLC. In this decade, affinity chromatography was invented, an ultra-violet (UV) detector was used for the first time in conjunction with LC, and, most importantly, the modern HPLC was born. Csaba Horvath led the development of modern HPLC by piecing together laboratory equipment to suit his purposes. In 1968, Picker Nuclear Company marketed the first commercially available HPLC as a “Nucleic Acid Analyzer.” The following year, the first international symposia on HPLC was held, and Kirkland at DuPont was able to functionalize controlled porosity pellicular particles for the first time. The 1970s and 1980s witnessed a renewed interest in separations media with reduced interparticular void volumes. Perfusion chromatography showed, for the first time, that chromatography media could support high flow rates without sacrificing resolution. Monoliths aptly fit into this new class of media, as they exhibit no void volume and can withstand flow rates up to 9mL/minute.
Prusiner of California named the prion, and thought that the protein did not require DNA to be made; the Institute of Molecular Systems Biology of ETH Zurich, and Charles Weiss mann, who looked for a section of mRNA that could make the protein, and in 1985 found a possible section of DNA; husband and wife, Harry Baker and Ros Ridley of the MRC in London discovered in 1989 that a genetic mutation could cause the prion to be made; seventeen possible genetic mutations were found in total in the UK; children treated with human growth hormone were found, in May 1985, to have CJD; Michael Preece of the UCL Great Ormond Street Institute of Child Health in London; more cases were found in France in 1992; scrapie in sheep; remains of sheep, in cattle feed caused BSE, which was discovered in 1986; Ray Bradley, head of BSE research at the Central Veterinary Laboratory; Graham Medley, a disease modeller at Imperial College, who looked at other modes of possible transmission, than contaminated animal feed; James Kirkwood, of the Institute of Zoology in London, and infection in the greater kudu; Gordon Hunter, veterinary researcher; Hamish Chalmers of Redesdale in Northumberland, and scrapie-resistant Swaledale sheep, which were bred at the Institute for Research on Animal Diseases (now the Pirbright Institute) at Compton, Berkshire; the amyloid beta protein of dementia, and research on marmosets. Narrated by Libby Purves, directed by John Bird, produced by Mike Johnstone, made by Langham Productions
Sources: en.wikipedia.org
Although often prevented and treatable if detected early, pressure ulcers can be very difficult to prevent in critically ill people, frail elders, and individuals with impaired mobility such as wheelchair users (especially where spinal injury is involved). Primary prevention is to redistribute pressure by regularly turning the person. The benefit of turning to avoid further sores is well documented since at least the 19th century. In addition to turning and re-positioning the person in the bed or wheelchair, eating a balanced diet with adequate protein and keeping the skin free from exposure to urine and stool is important. The rate of pressure ulcers in hospital settings is high; the prevalence in European hospitals ranges from 8.3% to 23%, and the prevalence was 26% in Canadian healthcare settings from 1990 to 2003. In 2013, there were 29,000 documented deaths from pressure ulcers globally, up from 14,000 deaths in 1990. The United States has tracked rates of pressure injury since the early 2000s. Whittington and Briones reported nationwide rates of pressure injuries in hospitals of 6% to 8%. By the early 2010s, one study showed the rate of pressure injury had dropped to about 4.5% across the Medicare population following the introduction of the International Guideline for pressure injury prevention. Padula and colleagues have witnessed a +29% uptick in pressure injury rates in recent years associated with the rollout of penalizing Medicare policies.
== Background == North Korea borders China and South Korea, two countries with early outbreaks. China is one of North Korea's closest allies, most important trading partner, and a source of tourists. The Chinese-North Korean border is porous, in contrast to the heavily militarized border between North and South Korea. However, suspected COVID-19 cases in the two Chinese provinces bordering North Korea (Liaoning and Jilin) have been low. Diplomatically and economically isolated, North Korea is an impoverished country with a weak healthcare system and is subject to sanctions, rendering it vulnerable in the event of an outbreak. In March 2020, there was concern that the country's widespread malnutrition could exacerbate the spread of COVID-19. In April, North Korean public health official Pak Myong-su said that if the disease spread in North Korea, "a serious disaster could not be avoided". The North Korean government is secretive, and the North Korean media is tightly controlled, making it difficult for observers to determine what is going on in the country. Historically, North Korea has restricted travel in the face of epidemics abroad, such as SARS in 2003 and the Western African Ebola virus epidemic in 2014. It eradicated measles in 2018, having a very efficient vaccination program managed by the Central Hygiene and Anti-Epidemic Institute, and the Hygiene and Anti-Epidemic Station, assisted by UNICEF and the World Health Organization (WHO). Given the supply of COVID-19 vaccines, the program could vaccinate the entire population with a first dose within weeks.
Freeman also narrated The True Story of Glory Continues, a documentary about the 54th Massachusetts Infantry Regiment. In 1992, he appeared in Clint Eastwood's western Unforgiven, which won four Academy Awards including Best Picture. The film depicts William Munny (Eastwood), an aging outlaw and killer who takes on one more job with old friend Ned Logan (Freeman). Unforgiven was widely acclaimed, with one critic calling Freeman's performance "outstanding". Also in 1992 Freeman starred in the John G. Avildsen directed drama The Power of One acting opposite Stephen Dorf and John Gielgud in a loose adaptation of Bryce Courtenay's 1989 novel of the same name, in which he plays boxing coach Geel Piet. In 1993, Freeman made his directorial debut with the drama Bopha!, which tells the story of a black policeman (Danny Glover) during South Africa's apartheid era. Bopha! was well-received, in particular for Freeman's directing. Hal Hinson of The Washington Post wrote: "Freeman lays out the father-son dynamics with great skill and very little fuss. There's no hysteria in his approach; instead, he sticks to the facts, relying on his cast to provide the emotion. The result is a surprisingly powerful, insightful film." Kenneth Turan from Los Angeles Times also complimented Freeman's direction but thought the film was "more predictable than powerful". In 1994, Freeman portrayed Red, the redeemed convict in Frank Darabont's acclaimed drama The Shawshank Redemption, with co-star Tim Robbins. It is based on the 1982 Stephen King novella Rita Hayworth and the Shawshank Redemption.
John K. Smith opened his first pharmacy in Philadelphia in 1830. In 1865, Mahlon Kline joined the business, which 10 years later became Smith, Kline & Co. In 1891, it merged with French, Richard and Company, and in 1929, changed its name to Smith Kline & French Laboratories as it focused more on research. Years later it bought Norden Laboratories, a business doing research into animal health, and Recherche et Industrie Thérapeutiques in Belgium in 1963, to focus on vaccines. The company began to expand globally, buying seven laboratories in Canada and the United States in 1969. In 1982, it bought Allergan, a manufacturer of eye and skincare products. Smith Kline & French merged with Beckman Inc. in 1982, and changed its name to SmithKline Beckman. In 1988, it bought International Clinical Laboratories.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.